Margaret Tempero, MD
Professor
Medicine
School of Medicine
margaret.tempero@ucsf.edu 415-353-7528
Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN. Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board.
Show full bio (170 words) Hide full bio
She codirected the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section and served as a member and Chair of the NCI Board of Scientific Counselors Subcommittee A. She is a member of the Scientific Steering Committee and Chair of the Clinical and Translational Study Section for the Cancer Prevention & Research Institute of Texas. She is or has been on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board, and the EORTC. She served as a member of the Oncology Drug Advisory Committee for the FDA. She has served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center. She is Chief Emeritus of the Division of Medical Oncology at UCSF. She served as the founding Deputy Director and was later Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center.
Awards
Show all (3) Hide
- Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
- Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
- Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012
Education & Training
Show all (1) Hide
- M.D. School of Medicine University of Nebraska 1977
Interests
Show all (13) Hide
- Cancer
- biomarkers
- quality of life
- antibodies
- clinical trials
- radioimmunoconjugate
- gastrointestinal cancers
- gemcitabine
- practice guidelines
- pancreatic adenocarcinoma
- immunotherapy
- CA 19-9
- pancreas
Websites
Show all (2) Hide
- Profile at UCSF Cancer Center (cancer.ucsf.edu)
- Clinical Profile at UCSF Medical Center (ucsfhealth.org)
Grants and Projects
Show all (6) Hide
- Buffett Cancer Center Support Grant, NIH, 1984-2026
- Cancer Center Support Grant, NIH, 1999-2023
- Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma, NIH, 2014-2018
- Mechanism-Based Evaluations of ErbB-Targeted Agents, NIH, 2001-2008
- Spore in Gastointestinal Cancer, NIH, 1997-2005
- Defining Toxicity and Benefit for Radioimmunotherapy, NIH, 1993-2000
Publications (282)
Top publication keywords:
Patient CareMedical OncologyAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsNeoplasmsHealth Care CostsOncologistsCarcinoma, Pancreatic DuctalAdenocarcinomaDeoxycytidineDrug ApprovalAntimetabolites, AntineoplasticPancreatic NeoplasmsReimbursement MechanismsCA-19-9 Antigen
-
ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
Annals of surgical oncology 2024 Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK -
Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
Annals of surgical oncology 2024 Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK -
Letter to Santa.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Giving Thanks.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
It Just Keeps Getting Better!
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M
Show all (277 more) Hide
-
Understanding Cancer Risk-Genes Matter!
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Being Sick Isn't Easy.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
A Glimpse Into the Future.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH,… -
"The Times They Are A-Changin' ".
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Clinical Trials: Does One Size Really Fit All?
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A -
I'm Getting Better at This!
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Dying in the Queue and Where Is My Nurse?
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Your Words Mean Something!
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Another New Beginning.
Journal of the National Comprehensive Cancer Network : JNCCN 2023 Tempero M -
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Journal for immunotherapy of cancer 2023 Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C,… -
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, … -
Letter to Santa.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Welcome Aboard!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
Annals of oncology : official journal of the European Society for Medical Oncology 2022 Seufferlein T, Uhl W, Kornmann M, Algül H, Friess H, König A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib… -
We Are Winning This War!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Together Again!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
My Report Card.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Failure Doesn't Feel Good!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
I Cannot Afford This!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Out in the World Again.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
It's OK to Share!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing.
Pancreas 2022 Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH -
Getting Complex Therapies to More People: A Vexing Dilemma.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
News About the Tiny Pharmacists Within Us.
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
American journal of clinical oncology 2022 Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH -
Starting Over, Again!
Journal of the National Comprehensive Cancer Network : JNCCN 2022 Tempero M -
Thank You, Santa!
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
ESMO open 2021 Sessa C, Cortes J, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J -
Reimagining Professional Meetings: Another Lesson From COVID-19.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Five Patients and One Important Lesson.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.
The oncologist 2021 Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M -
Targeting KRAS: Good, But Is It Good Enough?
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Something to Crow About!
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Pan-Cancer Screening: A Dream or a Nightmare.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.
Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi … -
Informed Consent: Is It Really?
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Open Notes Are Here: Are We Ready?
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Annals of surgical oncology 2021 Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC -
Being Closer to Normal.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, … -
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.
Cancer discovery 2021 Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, … -
It's All About Trust!
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Learning From Our Mistakes.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Annals of oncology : official journal of the European Society for Medical Oncology 2021 Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D… -
New Year's Resolutions - A Different Perspective.
Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tempero M -
Lasting Effects of COVID-19: Reimbursement Reform?
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Flirting With Disaster: COVID-19 and Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
COVID-19 and Cancer: Unintended Consequences.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
The Journal of clinical investigation 2020 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM… -
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L… -
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2020 Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL -
Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
AJR. American journal of roentgenology 2020 Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM -
I Can't Breathe!
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM -
My Two-Dimensional Life.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Lessons From a Tiny Strand of RNA.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt … -
Health and the Gut Microbiome: Who Knew?
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.
Pancreas 2020 Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY -
Taking Our Hands Off the Wheel.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
It's About Time!
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
This Time I Mean It!
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Tempero M -
CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
American journal of clinical oncology 2019 Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA -
Santa, Can You Hear Me?
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Giving Thanks.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
My Summer Vacation.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
We All Own This!
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A -
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Pancreas 2019 Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA -
Managing Expectations.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Taking the Mountain to Muhammad.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Tackling Cost: A Prescription for Spending Wisely.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Finding Room for Success.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
NCCN Guidelines Updates: Pancreatic Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero MA -
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
Familial cancer 2019 Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH -
The Time Has Come!
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
The American journal of surgical pathology 2019 Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE -
Pancreatic Adenocarcinoma, Version 1.2019.
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, … -
Kids, There's an App for That!
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
New Year, New Look!
Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tempero M -
An Oncologist's Letter to Santa: Bring Me Drugs!
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
I'm Conflicted. Are You?
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
One Size Fits All? Really?
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Getting What You Pay For: Finding Value in Cancer Care.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Notes From the Other Side.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
AJR. American journal of roentgenology 2018 Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA -
Genomic Medicine Takes the Stage, Again!
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Movin' On Up!
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Getting Into the Weeds.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Standing Together or Alone.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Molecular Diagnostics: Another Battle Brewing.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Extending Our Reach-Will Telemedicine Get Us There?
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
Revisiting New Year's Resolutions.
Journal of the National Comprehensive Cancer Network : JNCCN 2018 Tempero M -
It's About Time!
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies.
Cancer journal (Sudbury, Mass.) 2017 Tempero MA -
Who's Watching the Kids?
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
Oncotarget 2017 Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS -
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Future oncology (London, England) 2017 Doherty GJ, Tempero M, Corrie PG -
Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
The oncologist 2017 Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC -
Your Genes: Getting the Best Fit.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J… -
When It's Really Good, We Know It!
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Reducing the Cost of Cancer Care: When Less Is More.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Getting Practical About Recertification.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Active Systemic Treatment of Pancreatic Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Hospice: Angels at Work.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Politics as Usual-Not!
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Journal of the National Cancer Institute 2017 Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, … -
Saying Yes.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Mad About MACRA.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
New Year's Resolutions.
Journal of the National Comprehensive Cancer Network : JNCCN 2017 Tempero M -
Assessing Researcher Needs for a Virtual Biobank.
Biopreservation and biobanking 2016 van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S -
An Oncologist's Letter to Santa.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Hypermutation In Pancreatic Cancer.
Gastroenterology 2016 Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, … -
My Knee Hurts!
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
Pancreas 2016 Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK -
Crossing the Line.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Hillary and Donald, Our Patients Are Watching.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
I'll Have Another Shot, Please!
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Journal of surgical oncology 2016 Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH -
The Greatest Show on Earth!
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Did the IRB Approve This?
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Closely Guarded Secrets.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Pancreatic cancer.
Nature reviews. Disease primers 2016 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP -
Letting Nature Loose.
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Pancreas 2016 Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL -
Promising the Moon!
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Put Us Out of Business--Please!
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Bringing Biosimilars to the Clinic: What's the Fuss?
Journal of the National Comprehensive Cancer Network : JNCCN 2016 Tempero M -
Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies.
Journal of oncology practice 2016 Tempero M -
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
Cancer discovery 2015 Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM -
Paying Less for High-Value Care--Are You Kidding Me?
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
At Last: Getting Paid to Think!
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Putting an End to It!
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Crossing Over.
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM -
Move It!
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Express Scripts? Really?
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
Cancer discovery 2015 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA -
Improving Access to Drugs--Big Pharma Comes to the Table.
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Multidisciplinary management of pancreatic cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero MA -
Reducing costs by changing behavior-really?
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Turf war over diagnostic testing.
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Putting precision medicine on the national agenda.
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Whole genomes redefine the mutational landscape of pancreatic cancer.
Nature 2015 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, … -
All bundled up!
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, … -
Meet the New JNCCN!
Journal of the National Comprehensive Cancer Network : JNCCN 2015 Tempero M -
Happy anniversary!
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Bringing science to clinical practice.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Cancer screening: when is the juice worth the squeeze?
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.
NMR in biomedicine 2014 Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM -
Getting what you pay for: finding value in cancer care.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Incentive-based oncology: unintended consequences?
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, … -
A publicly funded clinical trials network: do we need it?
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Embracing team-based oncology care.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Managing the fruits of our success.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
Pancreas 2014 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH -
The changing face of community practice: the new normal.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
JNCCN going forward.
Journal of the National Comprehensive Cancer Network : JNCCN 2014 Tempero M -
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK -
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
British journal of cancer 2013 Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT -
Therapeutic advances in pancreatic cancer.
Gastroenterology 2013 Paulson AS, Tran Cao HS, Tempero MA, Lowy AM -
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, … -
Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM -
Monoclonal antibodies and other targeted therapies for pancreatic cancer.
Cancer journal (Sudbury, Mass.) 2012 Cinar P, Tempero MA -
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
Nature 2012 Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E… -
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
American journal of clinical oncology 2012 Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA -
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Cancer chemotherapy and pharmacology 2012 Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA -
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2012 Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, … -
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Nature medicine 2011 Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW -
Pancreatic cancer treatment and research: an international expert panel discussion.
Annals of oncology : official journal of the European Society for Medical Oncology 2011 Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E -
Blinded by the light: molecular imaging in pancreatic adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Collisson E, Tempero M -
Pancreatic adenocarcinoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2010 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura … -
International network of cancer genome projects.
Nature 2010 International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, … -
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Cancer chemotherapy and pharmacology 2010 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA -
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, … -
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ -
Personalized medicine for pancreatic cancer: a step in the right direction.
Gastroenterology 2008 Ko AH, Tempero MA -
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Pancreas 2008 Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA -
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
Annals of oncology : official journal of the European Society for Medical Oncology 2008 Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, … -
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Investigational new drugs 2008 Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA -
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Cancer investigation 2008 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA -
How I treat pancreatic ductal adenocarcinoma.
Journal of oncology practice 2008 Tempero MA -
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007 Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C -
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
Annals of oncology : official journal of the European Society for Medical Oncology 2007 Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, … -
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
International journal of radiation oncology, biology, physics 2007 Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA -
Workshop on imaging science development for cancer prevention and preemption.
Cancer biomarkers : section A of Disease markers 2007 Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg … -
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2006 Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S -
Pancreatic cancer in mice and man: the Penn Workshop 2004.
Cancer research 2006 Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA -
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA -
Systemic therapy for pancreatic cancer.
Seminars in radiation oncology 2005 Ko AH, Tempero MA -
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2005 Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler … -
Treatment of metastatic pancreatic cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2005 Ko AH, Tempero MA -
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
British journal of cancer 2005 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA -
Clinical oncology 2004: the president's report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Tempero MA -
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J -
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
International journal of gastrointestinal cancer 2003 Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA -
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2002 Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A -
Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002 Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J -
Current and future strategies for combined-modality therapy in pancreatic cancer.
Current oncology reports 2002 Ko AH, Tempero MA -
Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996) 2002 Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA -
A white paper: the product of a pancreas cancer think tank.
Cancer research 2001 Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA -
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001 Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM -
Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M -
Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK -
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D -
Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
Leukemia & lymphoma 2000 Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO -
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000 Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM -
Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.
Cancer chemotherapy and pharmacology 2000 Gwilt P, Tempero M, Kremer A, Connolly M, Ding C -
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association.
Gastroenterology 1999 DiMagno EP, Reber HA, Tempero MA -
Pancreatic cancer.
Current opinion in oncology 1998 Brand RE, Tempero MA -
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Cancer 1998 Tempero MA, Brand R -
Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy.
Journal of vascular and interventional radiology : JVIR 1998 Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA -
Biologic therapy of gastrointestinal cancer.
Cancer treatment and research 1998 Tempero M -
High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997 Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D -
Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997 Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA -
Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist.
Annals of the New York Academy of Sciences 1997 Tempero MA -
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Investigational new drugs 1997 Brand R, Capadano M, Tempero M -
Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.
Journal of clinical immunology 1997 Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D -
NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.) 1996 Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M -
Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes.
Biochimica et biophysica acta 1996 Haga Y, Tempero MA, Zetterman RK -
Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes.
Digestive diseases and sciences 1996 Haga Y, Tempero MA, Kay D, Zetterman RK -
Unconjugated bilirubin inhibits in vitro major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes.
Biochimica et biophysica acta 1996 Haga Y, Tempero MA, Zetterman RK -
Radiolabeled iododeoxyuridine: safety evaluation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996 Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK -
Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995 Sivinski CL, Lindner DJ, Borden EC, Tempero MA -
New imaging techniques in colorectal cancer.
Seminars in oncology 1995 Tempero M, Brand R, Holdeman K, Matamoros A -
Diagnostic use of radiolabeled antibodies for cancer.
Oncology (Williston Park, N.Y.) 1995 Harrison KA, Tempero MA -
Malignancies after liver transplantation: a comparative review.
Seminars in liver disease 1995 Tan-Shalaby J, Tempero M -
Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization.
Journal of hematotherapy 1995 Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI -
Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of cellular cytotoxicity.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995 Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, Thiele G -
Hypersensitivity to therapeutic murine monoclonal antibodies.
The Nebraska medical journal 1994 Kornbrot B, Kobayashi RH, Singer A, Tempero MA, Heiner DC -
Progress in colon cancer: do molecular markers matter?
The New England journal of medicine 1994 Tempero M, Anderson J -
The effect of garlic extract on human metabolism of acetaminophen.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1994 Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL -
Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.
International journal of pancreatology : official journal of the International Association of Pancreatology 1994 Haga Y, Sivinski CL, Woo D, Tempero MA -
Cancer therapy using radioimmunoconjugates. Implications for breast cancer.
Annals of the New York Academy of Sciences 1993 Tempero M, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E -
Pitfalls in antibody imaging in colorectal cancer.
Cancer 1993 Tempero M -
Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas.
Carcinogenesis 1992 Hirota M, Pour PM, Tempero MA, Chaney WG -
Flow cytometric measurement of intracellular bilirubin in human peripheral blood mononuclear cells exposed to unconjugated bilirubin.
Clinical biochemistry 1992 Haga Y, Kay HD, Tempero MA, Zetterman RK -
Characterization of bilirubin transport system by human peripheral blood mononuclear cells.
Journal of leukocyte biology 1992 Haga Y, Tempero MA, Kay HD, Zetterman RK -
Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992 Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG -
Progress in chemoprevention of gastrointestinal cancers.
Current opinion in oncology 1991 Tempero MA -
Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters.
The American journal of pathology 1991 Egami H, Tomioka T, Tempero M, Kay D, Pour PM -
Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.
International journal of pancreatology : official journal of the International Association of Pancreatology 1991 Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P -
Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990 Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD -
Advances in the medical management of advanced gastrointestinal cancers.
Current opinion in oncology 1990 Tempero MA -
Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment.
Cancer research 1989 Tempero MA, Nishioka K, Knott K, Zetterman RK -
Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases.
Human pathology 1989 Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM -
Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.
Proceedings of the National Academy of Sciences of the United States of America 1989 Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D -
Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.
The American journal of surgical pathology 1989 Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, Pour PM -
Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.
International journal of cancer 1988 Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM -
Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.
Cancer research 1988 Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z -
Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1988 Ness MJ, Pour PM, Tempero MA, Linder J -
Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Cancer research 1988 Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM -
Relationship of dietary cholesterol and cellulose in the prevention of colon cancer.
Cancer detection and prevention 1988 Tempero MA, Knott KK, Zetterman RK -
Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment.
Journal of surgical oncology 1987 Tempero MA, Zetterman RK -
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Cancer research 1987 Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM -
Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue.
International journal of pancreatology : official journal of the International Association of Pancreatology 1987 Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM -
Correlative studies on antigenicity of pancreatic cancer and blood group types.
Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc 1987 Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM -
In vitro regulation of human lymphocyte proliferation by selenium.
Biological trace element research 1986 Petrie HT, Klassen LW, Tempero MA, Kay HD -
The effect of selenium on cell proliferation in liver and colon.
Biological trace element research 1986 Tempero MA, Deschner EE, Zedeck MS -
Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Hybridoma 1986 Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H -
Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.
Hybridoma 1986 Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z -
The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986 Tempero MA, Williams CA, Anderson JC -
The importance of luminal factors in neomucosal growth.
The Journal of surgical research 1986 Thompson JS, Tempero MA, Haun JL, Vanderhoof JA -
Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review.
Digestive diseases (Basel, Switzerland) 1986 Tempero M -
The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysis.
JAMA 1985 Berg AR, Linder J, Anderson RW, Tempero MA, Edney JA, Armitage JO -
Thrombocytopenia and laboratory evidence of disseminated intravascular coagulation after shunts for ascites in malignant disease.
Cancer 1985 Tempero MA, Davis RB, Reed E, Edney J -
Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer.
Biological trace element research 1984 Tempero MA, Jacobs MM, Lynch HT, Graham CL, Blotcky AJ -
Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma.
Journal of surgical oncology 1982 Tempero MA, Kessinger A -
Detection of metastatic liver disease. Use of liver scans and biochemical liver tests.
JAMA 1982 Tempero MA, Petersen RJ, Zetterman RK, Lemon HM, Gurney J -
Disseminated Mycobacterium kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia.
Medical and pediatric oncology 1981 Tempero MA, Smith PW -
VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.
Cancer clinical trials 1981 Tempero M, Kessinger A, Lemon HM